Insights

World Courier

Cryogenic logistics: Meeting the demands of advanced therapies

World Courier

Manufacturers

Manufacturers

Manufacturers

Manufacturers

Manufacturers

Manufacturers

Manufacturers

Manufacturers

Manufacturers

How can FTZs help with commercialization success? What should manufacturers consider when evaluating a FTZ and 3PL partner?

Manufacturers

What are FTZs and why should pharma use them?

Manufacturers

How third-party logistics (3PL) solutions can help cell and gene therapy manufacturers manage the financial aspects of launching new therapies.

Manufacturers

Manufacturers

Manufacturers

Manufacturers

Manufacturers

Manufacturers

Manufacturers

Manufacturers

Manufacturers

Manufacturers

Manufacturers

Manufacturers

Manufacturers

Manufacturers

Manufacturers

Manufacturers

Manufacturers

Manufacturers

Manufacturers

Manufacturers

Manufacturers

Manufacturers

Insights

Cryogenic logistics: Meeting the demands of advanced therapies

Case study: Expertise ensures expedited on-boarding and launch processes

Streamlining 3PL logistics: Our approach to efficiency, innovation, and superior client service

Essential guide to cell and gene therapy (CGT) commercialization

ICS: Navigating the global healthcare landscape with 3PL

Case study: Foreign trade zone expedites speed to market

White paper: Navigating new U.S. serialization requirements for pharmaceutical logistics success

ICS: Developing innovative products and supply chain solutions

Can your 3PL partner grow with you? - Part one

Serialization will shape the future of the pharma industry

Building a serialization blueprint: early planning drives success

ICS’s parent company AmerisourceBergen becomes Cencora

Can your 3PL partner grow with you? - Part five

Can your 3PL partner grow with you? - Part four

Can your 3PL partner grow with you? - Part three

Can your 3PL partner grow with you - Part two

ICS: Advice for cell and gene therapy manufacturers amid medical breakthrough

AmerisourceBergen will become Cencora in 2023

ICS and World Courier: impacting the health and future of patients with failing hearts

Specialty 3PL & the Client Experience Pt. 1

Specialty 3PL & the Client Experience Pt. 2

COVID-19: Mitigating the Impact on your Supply Chain

Case Study: Partnerships Power New Drug Applications

ICS: Creating a successful commercialization journey for your product Pt.2

ICS: Creating a successful commercialization journey for your product Pt.1

Case Study: From RFP to Launch in Just Four Months

The Role of Foreign Trade Zones in Pharmaceutical Manufacturing Success: Part Two

The Role of Foreign Trade Zones in Pharmaceutical Manufacturing Success: Part One

Financial Management for Cell and Gene Therapies

ICS: Transitioning 3PL Partners

ICS: Logistics decisions impacting new cell and gene therapies

What ISO 9001:2015 means for pharmaceutical manufacturers

ICS: Serializing Your Products

Three Ways Title Model Powers Pharma Innovation

ICS: Life-changing launch

ICS: Connecting The Data Dots

ICS: Are You Prepared for DSCSA?

One nation, under the drug supply chain security act

ICS: Making a case for Title Model

Three Critical Components of the Specialty 3PL Experience

Driving New Value from 3PL Data Part 2

Driving New Value from 3PL Data Part 1

Executive Q & A: Models Matter

The New Four Ps of Cold Chain Management

Drug Quality and Security Act Podcast Part 2

ICS: Partnering for Packaging

ICS explains the specifics of ISO 9000

Drug Quality and Security Act Podcast Part 1

Why ISO 9000 Certification Matters to Manufacturers

Understanding ISO 9000 Certification

Value of ISO 9000 certification in pharmaceutical logistics